Published in Crit Rev Immunol on January 01, 2001
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 1.89
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis (2009) 1.58
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets (2005) 1.01
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med (2010) 0.97
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. Prostate (2009) 0.93
Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm (2014) 0.91
PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate (2012) 0.91
Chemically synthesized molecules with the targeting and effector functions of antibodies. J Am Chem Soc (2014) 0.89
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One (2011) 0.88
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78
Development of targeted near-infrared imaging agents for prostate cancer. Mol Cancer Ther (2014) 0.78
A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol (2015) 0.77
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine. Curr Opin Oncol (2016) 0.77
Theranostic imaging of cancer. Eur J Radiol (2012) 0.75
Aptamers for Targeted Drug Delivery. Pharmaceuticals (Basel) (2010) 0.75
(177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics (2017) 0.75
Theragnostic ultrasound using microbubbles in the treatment of prostate cancer. Ultrasonography (2016) 0.75
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science (1994) 4.81
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Identification and molecular characterization of csrA, a pleiotropic gene from Escherichia coli that affects glycogen biosynthesis, gluconeogenesis, cell size, and surface properties. J Bacteriol (1993) 3.39
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature (2000) 2.84
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Impact of education for physicians on patient outcomes. Pediatrics (1998) 2.54
Management of chronic disease by practitioners and patients: are we teaching the wrong things? BMJ (2000) 2.42
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol (1987) 1.87
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol (2000) 1.67
A model of self-regulation for control of chronic disease. Health Educ Behav (2001) 1.64
Identification of the Epstein-Barr virus gp85 gene. J Virol (1988) 1.61
The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol (2000) 1.60
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (1999) 1.44
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr (1997) 1.43
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology (2001) 1.41
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (2002) 1.36
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A (1994) 1.34
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
Long-term effects of asthma education for physicians on patient satisfaction and use of health services. Eur Respir J (2000) 1.32
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med (1998) 1.30
Prostate-specific membrane antigen. Prostate (1997) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A (2001) 1.22
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 1.22
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene (2011) 1.20
Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res (1995) 1.20
Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ (1996) 1.17
Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Semin Hematol (1998) 1.16
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Genetic and physical mapping of the regulatory gene csrA on the Escherichia coli K-12 chromosome. J Bacteriol (1993) 1.13
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
Physician-patient partnership in managing chronic illness. Acad Med (1995) 1.10
Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta (1998) 1.09
Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res (1999) 1.07
Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood (2001) 1.06
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol (2000) 1.05
Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood (2000) 1.01
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev (1999) 0.99
Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep (1977) 0.99
AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology (1994) 0.98
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol (1982) 0.97
Multimodality treatment of squamous cell carcinoma complicating pilonidal disease. Am Surg (1996) 0.97
Methods for the construction of retroviral vectors and the generation of high-titer producers. Methods Mol Med (1997) 0.96
A re-appraisal of treatment in chronic bacterial prostatitis. J Urol (1979) 0.96
Active site-directed double mutants of dihydrofolate reductase. Cancer Res (1996) 0.95
Involvement of interleukin-3 in delayed-type hypersensitivity. Blood (1998) 0.95
Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood (1997) 0.95
Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol (2000) 0.95
Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res (1994) 0.94
Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther (2006) 0.94
The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther (1997) 0.94
Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther (2000) 0.94
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology (1997) 0.93
Effect of head positioning in panoramic radiography on vertical measurements: an in vitro study. Dentomaxillofac Radiol (1996) 0.93
High energy shock waves suppress tumor growth in vitro and in vivo. J Urol (1986) 0.91
"Malgun" (clear) cell change of gastric epithelium in chronic Helicobacter pylori gastritis. Pathol Res Pract (2000) 0.91
Androgen, estrogen and progesterone receptors of the R3327H Copenhagen rat prostatic tumor. Cancer Lett (1979) 0.90
The regulation of nuclear DNA template restrictions by acidic polymers. Adv Enzyme Regul (1974) 0.90
TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin. Prostate (1994) 0.90
A scale for Assessing Health Care Providers' Teaching and Communication Behavior regarding asthma. Health Educ Behav (1997) 0.89
Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection. J Gene Med (2000) 0.89
Enhanced vascular contractility and diminished coronary artery flow in rats made hypertensive from diet-induced obesity. Int J Obes (Lond) (2006) 0.88
Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res (2000) 0.88
Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J Immunol (2001) 0.88
Histopathologic and ultrastructural correlates of tumor growth suppression by high energy shock waves. J Urol (1987) 0.87
Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol (1982) 0.87
Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics (1995) 0.87
Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res (1989) 0.86
Upregulation of caspase-3 expression in esophageal cancer correlates with favorable prognosis: an immunohistochemical study from a high incidence area in northern China. Dis Esophagus (2010) 0.85
Effect of hypnotics on mice genetically selected for sensitivity to ethanol. Pharmacol Biochem Behav (1976) 0.85
A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics (2001) 0.84
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res (2000) 0.84
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology (2001) 0.84
Investigation of the local chemical interactions between Hg and self-assembled monolayers on mesoporous supports. J Synchrotron Radiat (1999) 0.84
Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res (1994) 0.83
Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. Blood (2000) 0.83
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res (1999) 0.83
Cytotoxic and non-cytotoxic N-alkyl derivatives of putrescine: effect on polyamine uptake and growth of prostatic cancer cells in vitro. Biochem Pharmacol (1987) 0.83
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate (2000) 0.83
Free radical production by high energy shock waves--comparison with ionizing irradiation. J Urol (1988) 0.83
Establishment and characterization of an in vitro clonogenic cell assay for the R-3327-At Copenhagen rat prostatic tumor. Cancer Res (1978) 0.83
A promising genetic approach to the treatment of beta-thalassemia. Trends Cardiovasc Med (2001) 0.82